NFKB1 and diabetes mellitus: Evidence suggests that Sirolimus inhibits Nuclear Factor-kappaB (NF-kB) – a key inflammatory substance that is released upon device induced injury by the balloon and the stent deployment.26 This kinetics of initial burst of drug release followed by a sustained controlled release of sirolimus could actually explain the consistent results observed in the present registry across the different subgroups of patient with or without diabetes as compared to the other similar generation DES.